Renta 4| Grifols (GRF) has announced the appointment of Nacho Abia as the new CEO, replacing Thomas Glanzmann who will continue in the role of executive
Grifols, a global leader in plasma medicines, has received approval from the U.S. Food and Drug Administration for its new immunoglobulin (Ig) purification and filling facility at its Clayton manufacturing campus, one of the world’s largest sites for producing plasma-derived medicines.
Nuria Pascual: Hello, everyone, and welcome to the Grifols Third Quarter 2023 Conference Call. Thank you very much for taking the time to join us today.
Nuria Pascual: Hello everyone, and welcome to the Grifols Second Quarter 2023 Conference Call. Thank you very much for taking the time to join us today.